Zacks Investment Research upgraded shares of Leap Therapeutics (NASDAQ:LPTX) from a hold rating to a buy rating in a research report released on Tuesday morning. The brokerage currently has $7.00 target price on the stock.

According to Zacks, “Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. “

Shares of Leap Therapeutics (NASDAQ:LPTX) traded up $0.06 during midday trading on Tuesday, hitting $6.28. 27,422 shares of the stock were exchanged, compared to its average volume of 55,922. The stock has a market capitalization of $75.73 and a PE ratio of -1.82. Leap Therapeutics has a 1 year low of $4.90 and a 1 year high of $10.10.

Leap Therapeutics (NASDAQ:LPTX) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11). analysts forecast that Leap Therapeutics will post -3.63 earnings per share for the current year.

In other news, COO Augustine Lawlor acquired 1,057,769 shares of Leap Therapeutics stock in a transaction dated Tuesday, November 14th. The stock was purchased at an average cost of $6.09 per share, with a total value of $6,441,813.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 58.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at

About Leap Therapeutics

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with's FREE daily email newsletter.